rapid tests for detecting many infectious agents in the clini cal laboratory. Immunoassays for infectious pathogens include the traditional radioimmunoassay and the more recent enzyme-linked immunosorbent assay (ELISA). which allows numerou s different configurations of antigen and antibody. Most immuneassays u se primary antibodies (either polyclonal or monoclon al) directed against specific epitopes of the infectio us agent; the amount of primary a ntibody bound via a second antibody subsequently is quantitated by tagging with an easily identifia ble ma rker. Despite tl1e gen eral success of this a pproach . effective in1munoassays for certain infectious agents h ave been very d ifficu lt to develop, prompting investigators to search for a lternatives in the design of rapid immunological tests.
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A recent strategy taken by the a utl1ors' laboratory has exploited llie idiotype network of the immune system to develop novel reagents for improved detection of microbia l antigens. The highly specific antibodies generated during an immune response contain combining s ites with structural complementarity to t h e epitope of the target antigen. The hypervariable region of the immunoglobulin molecule, which forms the antibodycombining site and is responsible for defining the specificity of tl1e antibody, also carries a uniqu e set of antigen ic determinants, which collectively a re termed the idiotype of that antibody. These idiotypic d eterminants are antigenic , and as such may stim ula te the formation of anti-idiotype antibodies (Figure 1) . Studies from many la boratories h ave confirm ed tha t the combining s ite of some of the anti -idiotype antibodies fun c- tionally will mimic the conforma tion of tl1e original ep itope . representing its ·inte rnal image' (1-5). These p a rtic ula r a nti -idiotype a ntibodies . tl1us . can substitute for U1 e antigen in primary antibody binding.
Mu ch of tl1e evidence for tl1e a bility of anti-idiotype a ntibodies to act as s urrogate antigens h as been provided by research into tl1e development of a ntiidiotype vaccines. In recent years . anti -idiotype a ntibodies h ave been used to immunize e:>.. lJerimental anin1als against a variety of viruses. bacteria and parasites (6.7). The anti-anti-idiotype response indu ced in tl1e hosts against llie nomina l paU1ogen h as included development of protective immunity (eg. for h epatitis B virus. Streptococcus pneumoniae a nd Trypanosoma rlwdesiense). production of viral n e utralizing a ntibodies (eg. for poliovirus type II a nd rabies virus) a nd s timula tion of cell-mediated immunity (eg. for Sendai virus and reovirus type 3).
Observations such as t hese have not only demonstrated U1e vaccine potential of a nti -idiotype a ntibodies. but also suggested that U1 ey might be u seful tools for improved immunodetection of infectious agents. As for otl1er immunoassays. tl1e partic ular details of any protocol m ay be varied considerably. But tl1e essence of an a nti -idiotype immunoassay lies in the structural s imila ri ty between llie anti-idiotype and tl1e target epitope fo r tl1e prima ry a ntibody, such that on e m ay substitute for the ot11er in binding to tl1at a ntibody. An example of a n a nti-idiotype assay is s h own in Figure 2 .
In a n inhibition a ssay. when antigen (present in the test sample) is a llowed to bind to a s pecific a ntibody. s ubsequ ent interaction between the antibody and complem entary anti-idiotype a ntibody will be blocked (compa red willi a co ntrol in which no antigen is present). The inhibition of binding between idiotype a nd a ntiidiotype can be quantitated . and will refl ect tl1e concentration of antigen present in the test sample. Altern atively. competitive immunoassays could be establis h ed, willi labelled anti -idiotype a ntibodies competing with a ntigen for binding to a s pecific antibody. Given th e variety of existin g immunoassays for infectiou agen ts. wh at advantages migh t be expected from a n li-idiotype assays? First. th ere are m any complex m icrobia l an tigens whic h a re d iffi cult to obta in in pu rifi ed form ; by gen era ting an ti -idiotype antibodies. purified protein sub s tit u tes for th ese a n tigens can be used. Second. certain antigen s m ay h ave few exposed epitopes to any particular an tibody; th us. sandwich immunoassays -\.vhich require a minim u m of two accessible bindin g s ites -are n ot s u ccessful. Third . in ce rtain configurations s u c h as compe titive ass ays , it may be possible to achieve greater sen s itivi ty u s in g a n ti-idiotype a ntibod ies tha n othe rwise is possible .
As a m odel system to te t t h e feasibility of this co ncept. Brodeu r et al recently developed an a ntiidiotype ELISA for human cytomegaloviru s (HCMV) . HCMV is a s low growing virus . a nd curren t immuneassays for the virus in the clinical la boratory a re n ot ideal. The a uthors used a highly n eu tralizin g a nli -HCMV a n ti body (CMVBl) and gen erated m on oclonal anti-idiotype antibodies agains t it. Th e an ti -idiotype antibod ies exhibited properties tl1 at indicated they were ideal can didates fo r a ssay development: in pa r ticu la r. they completely inhibited tl1 e reactivity of CMVB 1 toward s its viral antigen (8) . Th e a nti -idiotype inhibition ELISA was develop ed with a la bora tOiy s tra in of HCMV . followi ng the s trategy outl in ed in Figure 2 . The assay was able to detect HCMV a nd m eas ured viral a n tigen in a dose-dependen t m ann er over a clinically relevant range (20 to 0.6x l 0 3 pla que fo rm ing uni ts p er millili tre of urine). Th ese en couraging result h ave prompted tl1e authors· fu rther evalu a tion of tl1 e assay wi th clin ical specimen s. Th ere is widespread interest in idiotypes and antiidiotypes for their role in regula ting the immun e respon se. as prob es for variou s cellula r receptors and a pos ibl e vaccines agains t tumours a nd infectio u s agen ts. Anti-idiotype a ntibodies as potential reagen ts fo r in vitro immunoassays can n ow be a dded to tl1is list. To the c urren t workers· knowledge. n o other repor ts in the scie n tific literature h ave in vestigated tl1e a pplicabil ity of tl1is idea. Non e theless. it em s likely U1 a t 320 A. Test Sample B. Control Figure 2 ) Illustration of a n a n t i-idiotyp e inhib ition immunoas- an ti -idiotype antibod ies a r e poised to ta ke tl1eir place am ong other immunological reagen ts as a valu a ble opti on in the des ign of fu t ure immunodiagnostics for infectiou s agents .
